Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2025.
Financials
Financial year 2025
Trince from Gent, company number BE0774374358, closed financial year 2025 with a result of € -1.6 million after tax. For that financial year Trince recorded a gross margin of € -74,970 and equity of € 7.2 million. Compared with financial year 2024, the result moved from € -1.6 million to € -1.6 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 19, 2026.
€ 7.2 million
▲ 106% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1.6 million
▲ 3 % less loss than in 2024
Profit after tax over the fiscal year.
€ 5.1 million
▲ € 4.3 million vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -5.8 million.
People and assets in 2025
11.2
▲ 1.9 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1 million
▲ 29% vs 2024
€ 91,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 50,738
▼ 53% vs 2024
Of which on lease € 10,984.
Debts at end 2025
€ 57,523
▼ 57% vs 2024
€ 36,987 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 233,809
▲ 61% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 159,423
▲ 22% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -582,497 | € -397,469 | € -233,556 | € -74,970 | ▲ € 158,586 |
| Profit after taxes | € -1,095,203 | € -1,441,718 | € -1,635,760 | € -1,591,440 | ▲ € 44,319 |
| Equity | € 2,293,547 | € 3,050,473 | € 3,489,580 | € 7,198,466 | ▲ 106% |
| Total debts | € 237,318 | € 1,302,168 | € 2,438,921 | € 1,540,698 | ▼ 37% |
| Cash | € 374,908 | € 441,286 | € 876,685 | € 5,127,765 | ▲ € 4.3 million |
| Retained profit | € -1,095,203 | € -2,536,922 | € -4,172,681 | € -5,764,122 | ▼ € 1.6 million |
| Bank debt | € 108,977 | € 146,809 | € 132,692 | € 57,523 | ▼ 57% |
| Balance sheet total | € 2,530,865 | € 4,352,641 | € 5,928,501 | € 8,739,164 | ▲ 47% |
| Employees (FTE) | 2.3 | 5.6 | 9.3 | 11.2 | ▲ 1.9 |
Key figures of Trince, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Trince?
What happened at Trince in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- BACON INVEST BV stepped down as director. NBB
- CASSEL BV stepped down as director. NBB
- Qbic Venture Partners II NV stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 1.6 million. Source: NBB ↗
- BACON INVEST BV became a director. NBB
- Patrick Keereman stepped down as director. NBB
- CASSEL BV became a director. NBB
- Novalis II CommV became a director. NBB
In short
From € 1.1 million loss in 2022 to € 1.6 million loss in 2025.
Management
The stake of Novalis II, QBIC II FUND ARKIV, BACON INVEST comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
TrinceBehind Trince are Novalis II CommV and THEIA INNOVATIONS. The shares are held by Novalis II (14.8%), QBIC II FUND ARKIV (11.9%) and BACON INVEST (5.3%).
Directors
According to the 2025 annual accounts
since 2025
Persoon belast met dagelijks bestuur, Director · represented by Kevin Braeckmans
since 2025
Daisy Flamez
Director
since 2021 · until 2025
Philip Mathuis
Director
since 2024 · until 2025
since 2026 · until 2032
Patrick Keereman
Director
since 2021 · until 2026
Director · represented by Walter Mastelinck
Also active at: CREAPLAN, WATT FACTORY, CLOUDS OF CARE, Sigma Invest, Lina Invest, Heimat, VINDEVOGEL FLANDERS, BETOTRACE +4 more
since 2026 · until 2032
Director · represented by Cédric Van Nevel
Also active at: EYED PHARMA, Accelleran, Indigo Diabetes, QBIC II FUND ARKIV, Blue Foot Membranes, Aloxy, Sentea, UniD Manufacturing +4 more
since 2024 · until 2027
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Ottergemsesteenweg-Zuid 731
9000 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Certifications & Partners
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Domain
Domain
trincebio.com
Registered
2019-08-22
Registrar
Combell NV
Expires
2026-08-22
Website info
Features
Security
Network
Details
- Company number
- 0774.374.358
- VAT number
- BE 0774.374.358
- Registered office
- Ottergemsesteenweg-Zuid 731, 9000 Gent
- Names & denominations
- Trince
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 21 September 2021
- Peppol
- Active · Active since 7 Jul 2025
- Contact
- trincebio.com
- Activities · NACE
Activiteiten van ingenieurs en aanverwante technische adviseurs, exclusief landmeters-experts
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering